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Minimal Role of Enhanced Cell Proliferation in
Skin Tumor Promotion by Mirex:
A Nonphorbol Ester-Type Promoter
by Sharon A. Meyer,1 Glenda J. Moser,1 Nancy A. Monteiro-
Riviere,1 and Robert C. Smart1
Mirex, a chlorinated hydrocarbon previously used as a systemic insecticide and flame retar-
dant, is a nongenotoxic hepatocarcinogen in both rats and mice. In liver, mirex induced bio-
chemical responses and hyperplasia characteristic ofincreased cell proliferation, which is con-
sistent with its role as a liver tumor promoter. We have recently shown that mirex is a potent
nonphorbol ester-type skin tumor promoter in 7, 12-dimethylbenz[a]anthracene (DMBA)-initiat-
ed mice. However, unlike its effect in liver, a single topical application ofmirex to skin does not
induce the acute biochemical responses, such as increased epidermal DNA synthesis and
ornithine decarboxylase activity, indicative of increased cell proliferation. Multiple topical
applications ofmirex over a 1 month period induced only a minimal increase in the number of
epidermal nucleated cell layers, which contrasts with definitive hyperplasia induced by a com-
parable tumor-promoting dose of 12-0-tetradecanoylphorbol-13-acetate (TPA). Collectively,
these data indicated that mirex is promoting through a novel mechanism. Further evidence
that mirex promotes tumors through a mechanism distinct from that of the prototypical skin
tumor promoter, TPA, was obtained by examining the effect oftheir simultaneous co-treatment.
The co-application of mirex and TPA yielded a tumor multiplicity greater than the sum of the
responses of each promoter individually. In summary, our results demonstrate that mirex, a
carcinogenic and hyperplastic agent in liver, is also a very effective tumor promoter in mouse
skin, but suggest that mirex operates via a novel mechanism in skin that may involve only a
minimal role for enhanced cell proliferation.
Introduction
Recent studies on human colon cancer have suggest-
ed that multiple, cumulative genetic lesions are required
for carcinogenesis (1). However, approximately one-
third of the carcinogens detected in the National
Toxicology Program rodent bioassay are nongenotoxic
in short-term, in vitro tests (2) and thus may include
tumor promoters as defined by experimental models of
multistage chemical carcinogenesis. Tumor promoters
are carcinogens that have classically been thought to
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act through nongenotoxic mechanisms to expand popu-
lations of cells previously damaged by exposure to a
subcarcinogenic dose of a genotoxic initiating chemical
(3). Because previously identified tumor promoters
cause varying degrees of increased cell proliferation,
one explanation for their enhancement of carcinogene-
sis is that these compounds are indirectly genotoxic as
a consequence of increasing the occurrence of errors
normally made during DNA replication (4,5).
Mirex is a chlorinated hydrocarbon previously used
as a systemic insecticide and as a flame retardant. Its
use in the United States was banned by the Environ-
mental Protection Agency, in part because it is hepa-
tocarcinogenic in both rats and mice (6-9). Although it
has not been formally tested in an initiation-promotion
protocol for liver carcinogenesis, mirex is not genotox-
ic in short-term, in vitro tests (9,10) and inhibits gap
junctional communication (11), two characteristics of
tumor promoters. Mirex induces proliferation of
hepatocyte smooth endoplasmic reticulum (12,13) and
mixed-function oxidase activities (14,15), as alsoMEYER ETAL.
occurs during the adaptive response of liver to other
xenobiotic tumor promoters, such as phenobarbital
(16). Consistent with the above hypothesis relating
tumor promotion and cell proliferation, mirex stimu-
lates liver growth, in part through hyperplasia (17)
which is preceded by induction of ornithine decar-
boxylase activity (17,18) and stimulation of DNA syn-
thesis (17,19).
We have recently reported that mirex is a nonphor-
bol ester-type skin tumor promoter in 7,12-dimethyl-
benz[a]anthracene (DMBA)-initiated female mice (20).
A maximally promoting dose of mirex (200 nmole, 3
times/week) resulted in a tumorincidence of96% with a
multiplicity of 16 tumors/mouse, comparable to that
obtained with thrice weekly applications of 2 nmole of
12-O-tetradecanoylphorbol-13-acetate (TPA). However,
in contrast to the acute responses of skin to a single
application of TPA, mirex did not induce epidermal
ornithine decarboxylase activity or increase DNA syn-
thesis. Also, as illustrated here, chronic treatment with
200 nmole of mirex is associated with only a minimal
increase in the number ofnucleated epidermal cell lay-
ers, whereas 2 nmole of TPA causes definitive epider-
mal hyperplasia. Because these results suggested that
mirex promotes through a mechanism distinct from
that ofTPA, we tested the tumor response to co-appli-
cation of mirex and TPA. A greater than additive
response was observed. Collectively, these results sug-
gest that the mechanism through which mirex pro-
motes skin tumors may involve only a minimal
enhancement of cell proliferation. If so, then mirex-
induced skin tumor promotion may provide an impor-
tant exception to the hypothesis linking tumor promo-
tion and epidermal hyperplasia.
Methods
Morphological Examination. Female CD-1 mice
(6-8 weeks old) were purchased from Charles River
Laboratories (Raleigh, NC). Hair was removed from
the dorsal skin with electric clippers. One week later,
mice were treated topically three times per week for 4
weeks with 2 nmole TPA or 200 nmole mirex in 200 ,uL
acetone. Forty eight hours after the last application,
mice were killed and dorsal skins were excised and
fixed for 24 hr in 10% neutral-buffered formalin, were
processed routinely, and were then embedded in
paraffin. Approximately 5 ,um sections were stained
with hematoxylin and eosin and viewed for evidence of
hyperplasia and toxicity.
Tumor Promotion Experiments. Hair was removed
from the dorsal skin of female CD-1 mice (6-8 weeks
old) with electric clippers. One week later, mice
showing no signs of hair regrowth were initiated with
a topical application of200 nmole 7,12-dimethylbenz[a]
anthracene (DMBA) in 200 ,uL acetone. One week after
initiation, groups of 30 mice were promoted twice
weekly for 20 weeks by topical application of 2 nmole
TPA, 200 nmole mirex, or 2 nmole TPA plus 200 nmole
mirex. Mice that were promoted with acetone and mice
that were initiated with acetone and promoted with
mirex or TPA did not develop tumors. One tumor
occurred in an acetone-initiated group after 14 weeks
ofpromotion with mirex plus TPA.
Results
We have shown that mirex is a potent skin tumor
promoter in DMBA-initiated female CD-1 mice (20).
After 20 weeks of thrice weekly application, 50 nmole
mirex yielded 60% incidence of tumor-bearing mice
with an average multiplicity of 4 tumors/mouse, while
200 nmole mirex, maximal promoting dose, yielded
96% tumor incidence with a multiplicity of 16 tumors/
mouse. For comparison, thrice weekly application of 2
nmole TPA gave 78% tumor incidence with 15 tumors/
mouse. In contrast to the well-characterized biochemi-
cal responses to TPA, a single topical application of200
nmole mirex did not induce epidermal ornithine decar-
boxylase activity or increase DNA synthesis, as
assessed by [3H]thymidine pulse labeling. We have
evaluated time courses from 5 to 56 hr for ornithine
decarboxylase and from 18 to 108 hr for DNA synthe-
sis to encompass peak response times found with other
tumor promoters and have found no evidence ofstimu-
lation ofthese events by mirex (20).
As shown in Figure 1, we have morphologically
examined skins treated repeatedly (3 times/week for 4
weeks) with comparable promoting doses ofmirex (200
nmole) or TPA (2 nmole) for evidence of epidermal
hyperplasia. Multiple applications ofmirex for 1 month
resulted in only a minimal increase in the number of
nucleated epidermal cell layers, from one to two in ace-
tone-treated epidermis (Fig. 1A) to two to three in
mirex-treated epidermis (Fig 1C). In contrast, a defini-
tive hyperplastic response of six to seven nucleated
epidermal cell layers was observed after repeated
treatment with TPA; (Fig. 1B). Thus, these results
demonstrated that under conditions where both 200
nmole mirex and 2 nmole TPA give similar tumor
yields, only the TPA response was associated with the
biochemical markers of enhanced cell proliferation,
induction of epidermal ornithine decarboxylase activi-
ty and increased DNA synthesis, and significant
hyperplasia.
These contrasting responses of epidermis to mirex
and TPA suggested that distinct mechanisms could be
mediating their promotional activities. To test this
hypothesis, we determined the tumor response to
simultaneous cotreatment with mirex and TPA (Fig.
2). Co-application of 200 nmole mirex with 2 nmole
TPA twice weekly for 20 weeks on DMBA-initiated
mouse skin yielded a tumor multiplicity of 28 tumors/
mouse, compared with 14 tumors/mouse after mirex or
4 tumors/mouse after TPA treatment individually.
Rate of tumor incidence was accelerated by cotreat-
ment such that after 8 weeks of promotion, 90% of
cotreated mice bore tumors, compared to 47% or 17%
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FIGURE 1. Morphological examination of CD-1 mouse epidermis after thrice weekly application for 4 weeks of TPA or mirex. Dorsal skins of
mice were treated three times weekly with 200 gL ofacetone (A), 2 nmole TPA (B), or 200 nmole mirex (C) in 200 iL ofacetone. Mice were
killed 48 hr after the last treatment and the skin was removed and processed forlight microscopy. Final magnification is 220x.
of mice treated with mirex or TPA individually. Thus,
in addition to supporting distinct mirex- and TPA-
induced promotional mechanisms, these results further
indicate that these two mechanisms could complement
each other to yield a synergistic tumorresponse.
Discussion
We describe here results extending our previous
work (20) demonstrating that mirex is a potent tumor
promoter in DMBA-initiated mouse skin and that
mirex promotes skin tumors through a novel mecha-
nism involving minimal cell proliferation. Previously
we demonstrated the inability ofmirex to induce acute
biochemical responses indicative of increased cell pro-
liferation, i.e., increased epidermal DNA synthesis and
induction of ornithine decarboxylase activity, that are
generally observed in response to single applications of
other skin tumor promoters (20). Consistent with these
results, we have shown that multiple applications of
mirex over 1 month did not induce significant epider-
mal hyperplasia, especially when contrasted with the
response to a comparable tumor-promoting dose of
TPA (Fig 1). This observation is particularly support-
ive ofa mechanism for mirex-induced tumor promotion
that involves a relatively minor role for cell prolifera-
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FIGURE 2. Enhanced skin tumor promotion by co-application of
mirex and TPA. Groups of 30 CD-1 female mice were initiated
with 200 nmole ofDMBA, then 1 week later were promoted twice
weekly with either 200 nmole mirex (@), 2 nmole TPA (- ), or 200
nmole mirex plus 2 nmole TPA (A). None of the mice initiated
with acetone and promoted with mirex or TPA individually or
mice initiated with DMBA and promoted with acetone developed
tumors. One mouse initiated with acetone and promoted with
mirex plus TPA developed one tumor after 14 weeks.
tion, because sustained, chronic hyperplasia has been
considered one of the best correlates of skin tumor-
promoting activity (21).
Skin tumor promoters have been generally divided
into two classes, the phorbol ester-type and nonphor-
bol ester-type, depending on whether they activate
protein kinase C (PKC) enzymatic activity or compete
with TPAbinding to protein kinase C ofin vitro prepa-
rations (22-24). We have shown that mirex does not
activate brain or epidermal PKC in vitro (25) and thus
is a nonphorbol ester-type promoter. The implication
of this classiflcation is that the molecular targets of
nonphorbol ester-type promoters relevant to their pro-
moting activity are different from protein kinase C.
Potential targets have been identified for the nonphor-
bol ester-type promoter okadaic acid, an inhibitor of
protein phosphatase 1 and 2A (26), and for thapsigar-
gin, an inhibitor of the endoplasmic reticulum Ca2+-
ATPase (27). Further, nonphorbol ester-type and
phorbol ester-type tumor promoters can synergize in
the induction of common biological responses, such as
stimulation of arachidonic acid metabolism in C-9 rat
liver cells (28) and induction of gene expression from
AP-1 sites in Rat-1 cells (29). We have shown here that
mirex can synergize the TPA in the promotion of skin
tumors (Fig. 2). This result lends further support to
the hypothesis that mirex and TPA promote through
different mechanisms and suggests that these distinct
mechanisms can complement each other.
The extensive hyperplasia induced by TPA appears
to be a generalized response, i.e., it appears that all
basal cells of the epidermis are stimulated to prolifer-
ate. Our inability to detect mirex-induced biochemical
and morphological responses associated with increased
epidermal cell proliferation does not mean that cell
proliferation is not increased during mirex-induced
tumorpromotion. Ithas been emphasized that the hypo-
thesis relating tumor promotion to cell proliferation
predicts that proliferation will be stimulated in initiat-
ed cells (5). Thus, we speculate that mirex selectively
enhances proliferation ofinitiated epidermal cells with-
out inducing a generalized hyperplastic response. We
would thus not expect to see hyperplasia or increased
DNA synthesis in uninitiated skin, which is classically
used to evaluate these short-term responses. If this
speculation is true, then mirex could be an important
exception to the correlation that tumor-promoting
activity is related to sustained epidermal hyperplasia
(21). As such, mirex may provide a unique and impor-
tant tool for identification and study of early preneo-
plastic lesions in skin.
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